ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, curcumin in co-administration with imatinib has been reported in vitro to more potently suppress proliferation and promote apoptosis of BCR-ABL-positive CML cells than either agent alone.